Amla (Indian Gooseberry) in Ayurveda: Properties & Everyday Use

What it is

Amla, Indian gooseberry, amalaki: three names, one fruit. It comes from Phyllanthus emblica L., a tree native to India and Southeast Asia (Antioxidants review). Health Canada's natural health product monograph (2025, citing the Ayurvedic Pharmacopoeia of India 2001) lists the proper name Phyllanthus emblica, the common names amla, amalaki, and Indian gooseberry, and the dried fruit as the medicinal ingredient (Health Canada monograph). Research papers also cite the botanical synonym Emblica officinalis for the same species, so do not let the two Latin names confuse you into thinking two plants are being discussed (Upadya et al.). The fruit is noted for its vitamin C content (reported values of 193–720 mg/100 g across studies) and its polyphenols (Antioxidants review).

Classical properties

• Taste (rasa): sour (Amla)
• Qualities (guna): light (Laghu), oily (Snigdha)
• Potency (virya): cooling (Sheeta)
• After digestion (vipaka): sweet (Madhura)
• Doshas: traditionally described as balancing for all three

Traditional use

In Ayurveda, amla is classed as a rasayana, a rejuvenative. Health Canada's monograph records its traditional uses as a digestive tonic, for relief of dyspepsia and heartburn, as a mild laxative, and as an eye tonic (Health Canada monograph). A 2022 review notes amla's traditional role in Indian medicine for reducing anxiety and burning sensations in the skin and eyes, improving anemic conditions and male reproductive health, facilitating digestion, supporting liver health, and as a tonic for the cardiovascular system (Antioxidants review). Long list. Traditional claims, not clinical proof. The trial evidence is assessed separately below, and it is shorter than the traditional list.

What research has looked at

Blood lipids

The strongest human evidence concerns blood lipids, so start here. In a 2019 multicenter randomized, double-blind, placebo-controlled trial of 98 dyslipidemic adults, a standardized full-spectrum amla fruit extract taken for 12 weeks produced significantly lower total cholesterol (p=0.0003), triglycerides (p=0.0003), LDL cholesterol (p=0.0064) and VLDL cholesterol (p=0.0001) versus placebo, along with a 39% reduction in the atherogenic index of plasma (p=0.0177) (Upadya et al., BMC Complementary and Alternative Medicine). Strong numbers. Now the asterisk, because this one is doing heavy lifting: this was a proprietary extract (Arjuna Natural Ltd.). Its results do not automatically generalize to other amla products. Different bottle, different extract, different evidence.

A second 2019 randomized, double-blind, placebo-controlled trial in 59 adults with metabolic syndrome tested a standardized aqueous amla fruit extract at two strengths for 12 weeks and reported improvements in lipid, endothelial-function, oxidative-stress and inflammation measures versus placebo (Usharani et al.). Again, one specific standardized extract. We keep repeating that because it is the sentence most marketing leaves out.

A 2023 meta-analysis of nine RCTs (535 participants) found significant pooled reductions in LDL cholesterol, VLDL cholesterol, triglycerides and hsCRP, but noted meaningful heterogeneity between trials and cautioned against drawing firm conclusions about cardiovascular prevention (meta-analysis, Antioxidants). The authors did the honest thing: they reported the pooled win and then warned you not to overread it.

Blood sugar

A separate 2023 systematic review and meta-analysis of five RCTs found pooled reductions in fasting blood glucose (as well as LDL cholesterol, total cholesterol, triglycerides and CRP, with increased HDL cholesterol) across interventions lasting 3–12 weeks. The authors called for further trials to confirm the findings (PubMed). Calling for further trials is doing the right thing. It is also a signal that this is not settled.

An earlier, smaller human study gave amla fruit powder for 21 days and reported fasting and postprandial glucose and lipid improvements against baseline. But this was a weaker design than the later placebo-controlled trials, so we treat it cautiously, and you should too (Akhtar et al., 2011). And here is a detail we appreciate about the Upadya trial: it did not establish a glucose-lowering effect. Only eight participants had elevated baseline fasting glucose, and the authors said the hypoglycemic potential "needs reconfirmation in a larger study" (Upadya et al.). When a trial team declines to claim more than the data support, we pay attention.

Inflammation

Both 2023 meta-analyses reported pooled reductions in inflammatory markers (CRP and hsCRP) with amla supplementation over the short trial periods studied (PubMed; Antioxidants). These are biomarker changes. Not proof of clinical anti-inflammatory benefit. Blood markers moved; we will not tell you that means your joints feel better.

What the evidence does not support (yet)

All the trials above measured blood biomarkers over 3–12 weeks. No trial has tested whether amla prevents heart attacks, strokes, or other cardiovascular events, or whether it treats diabetes as a disease. The meta-analyses flag small samples, short durations, and heterogeneity. And to say the quiet part out loud: amla has not been shown to replace prescribed lipid-lowering or diabetes medication. Biomarkers are not outcomes, and short trials are not long trials.

Safety notes

Health Canada's monograph notes amla may have a laxative effect. Laxative use is contraindicated with fever or undiagnosed gastrointestinal trouble, amla products should be taken several hours apart from medications, and people who are pregnant or breastfeeding should consult a clinician first (Health Canada monograph). In the Upadya trial, four non-serious adverse events were reported: classified as mild, of possible relation to the product, and resolved with routine medications. Three occurred in the placebo group and one in the amla group (Upadya et al.). Long-term safety data beyond 12-week trials are lacking, and anyone taking prescription lipid- or glucose-lowering drugs should discuss amla use with their clinician. One more boundary worth knowing: the monograph excludes foods and food-like forms, so its cautions apply to medicinal amla products, not kitchen fruit.

FAQs

Does amla lower cholesterol?

In trials, yes for blood biomarkers. A 12-week RCT of 98 dyslipidemic adults found an amla extract significantly lowered total cholesterol, triglycerides, LDL-C and VLDL-C versus placebo (Upadya et al.), and a 2023 meta-analysis of nine RCTs found pooled reductions in LDL-C, VLDL-C and triglycerides (Antioxidants). Our standing caveat: the trials were short and used specific extracts.

Does amla lower blood sugar?

A 2023 meta-analysis of five RCTs found pooled reductions in fasting blood glucose over 3–12 weeks, but the authors called for confirmation (PubMed). A small 2011 study of amla fruit powder also reported glucose improvements, but with a weaker design (Akhtar et al.). Amla is not an established diabetes treatment, and we would not present it as one.

Can amla replace my statin or diabetes medication?

No. Trials measured short-term blood biomarkers and did not test amla against disease outcomes. None showed it can replace prescribed therapy. Do not stop or change prescribed medication without your clinician. This one is non-negotiable.

How much amla should I take?

Swastik does not suggest amounts. The right amount depends on the person, the preparation and the product, so check with a qualified Ayurvedic practitioner or your doctor before taking any herb.

Is amla safe?

In the largest published RCT, adverse events were mild and infrequent: one in the amla group, three in placebo (Upadya et al.). Health Canada cautions about a possible laxative effect, separating amla from medications by several hours, and consulting a clinician if pregnant or breastfeeding (Health Canada monograph). Long-term safety data are lacking, which is its own kind of answer.

Is fresh amla fruit or juice the same as the trial extracts?

No. The trials used standardized extracts, not fresh fruit or juice, and Health Canada's monograph explicitly excludes foods and food-like forms (Health Canada monograph). Effects shown for extracts have not been demonstrated for kitchen fruit or juice. The murabba on your shelf is not the trial intervention.

Sources

Health Canada's natural health product monograph for amla (2025, citing the Ayurvedic Pharmacopoeia of India 2001) is the backbone for the identity, traditional-use, and safety statements: webprod.hc-sc.gc.ca

The lead lipid trial is Upadya and colleagues' 2019 randomized, double-blind, placebo-controlled, multicenter clinical trial of Emblica officinalis extract in dyslipidemia, BMC Complementary and Alternative Medicine, 19:27, DOI 10.1186/s12906-019-2430-y (PMC · PMC6341673), the n=98 study behind the p-values and the safety data. The second lipid trial is Usharani and colleagues' 2019 randomized, double-blind, placebo-controlled study of Phyllanthus emblica extract in metabolic syndrome (PMC · PMC6503348).

The pooled evidence is two 2023 meta-analyses: the glycemic and lipid systematic review and meta-analysis of randomized controlled trials (PubMed · PMID 36934568) and the cardiovascular-risk-factor systematic review and meta-analysis of nine RCTs in Antioxidants (PMC · PMC10251691). The small early glucose study is Akhtar and colleagues, International Journal of Food Sciences and Nutrition 2011, 62(6):609–616 (PubMed · PMID 21495900), weaker design, cited with the caution it deserves. The botanical and traditional-use background is the 2022 comprehensive review of Phyllanthus emblica in Antioxidants, 11(5):816 (mdpi.com).

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.